Newspaper Advertisement regarding publication of Financial Results for the quarter and year ended March 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech Ltd has submitted newspaper clippings confirming publication of its audited standalone financial results for the quarter and full year ended March 31, 2025, in Financial Express (English) and Jansatta (Hindi) on June 1, 2025, as required under SEBI Listing Regulations. For Q4 FY25 (standalone), the company reported a net loss of about Rs 8.35 lakhs after tax, compared to a profit of Rs 15.54 lakhs in the previous quarter. However, for the full year FY25, net profit after tax stood at around Rs 35.61 lakhs, a sharp improvement from Rs 1.52 lakhs in FY24. Full-year basic and diluted EPS came in at Rs 1.17 versus Rs 0.05 last year. Total income from operations for FY25 was Rs 16.51 lakhs versus Rs 55.4 lakhs in FY24 (based on the extract), suggesting a notable decline in topline even as bottomline improved.
This is primarily a compliance filing for public dissemination of results, not a new business event. The mixed picture — quarterly loss but strong annual profit growth on lower revenue — may not drive a clear directional move in the stock; investors should look at the detailed results on BSE or the company website for segment-level clarity.